Rx For Immuno-Oncology Excess? Top US FDA Cancer Officials Take On Development ‘Wild West’
Executive Summary
Rapid, uncoordinated growth has turned the PD-1/L1 inhibitor pipeline into a global stampede, FDA’s Pazdur and Beaver say. Solutions like a unified submission pathway and coordinated trial design pose challenges requiring international cooperation among governments and industry alike.